Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2026Clinical and Translational MedicineOpen Access

ZC3H13‐mediated m6A stabilization of CCND1 promotes malignant progression and is associated with poor anti‐PD‐1 response in HNSCC

View Full Paper
Ask AI
Bookmark
Share

Authors

WCW H ChenYLYun LiSCS X Chen

Discussion

Loading...

Member takes

Overview

Randomized trial shows ZC3H13 affects tumor progression in HNSCC, suggesting it as a target for improving anti-PD-1 treatment efficacy.

Key Points

  • This research aims to understand the role of ZC3H13 in HNSCC progression and its impact on anti-PD-1 therapy response.
  • Evaluated ZC3H13 expression in clinical cohorts and transcriptomic datasets
  • Conducted gain- and loss-of-function experiments on HNSCC cells
  • Utilized a conditional knockout mouse model to study oral tumorigenesis and anti-PD-1 response
  • ZC3H13 was upregulated in HNSCC, correlating with poor prognosis and limited anti-PD-1 response
  • ZC3H13 enhanced proliferation and invasion of HNSCC cells; its ablation reduced oral tumorigenesis
  • ZC3H13 was found to stabilize CCND1 mRNA via N6-methyladenosine modification, promoting malignancy and resistance to therapy

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a69a2c7c8da07d9defa69c3https://doi.org/10.1002/ctm2.70750
View Full Paper
Ask AI
Bookmark
Share